相关实验视频

Updated: Sep 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

分析了来自土耳其参考中心在风湿病学实践中生物类似药物处方率的数据

Hüseyin Kaplan¹, Gizem Cengiz², Hasan Kara³

¹Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkey. hkaplan_87@hotmail.com.

Scientific reports

|August 6, 2025

概括

在轴性脊椎关节炎和类风湿性关节炎患者中,生物类似药 (BS) 的使用率为21.2%,独立于疾病类型. 随着更多的治疗切换和更晚的治疗线路,BS处方增加了.

科学领域:

类风湿病学类风湿病学
药物经济学药物经济学
药物开发药物开发

背景情况:

生物或向合成修饰疾病的抗风湿药物 (b/tsDMARDs) 对于管理炎症状况至关重要.
生物类似药 (BSs) 提供了潜在的成本节约和更多的治疗选择.
了解BS处方模式对于优化患者护理和资源配置至关重要.

研究的目的:

为了确定生物类似药 (BSs) 在接受b/tsDMARDs治疗的患者的利用率和处方率.
为了比较轴性脊柱关节炎 (axSpA) 和类风湿性关节炎 (RA) 患者之间的BS使用情况.
识别与BS处方模式相关的预测因素.

主要方法:

对647名axSpA和RA患者进行了回顾性研究.
对人口统计,临床和治疗数据的手动和电子患者记录的审查.
后勤回归分析以确定BS处方的预测因素.

主要成果:

总体上BS使用率为21.2%,axSpA (22.2%) 和RA (19%) 组之间没有显著差异.
随着治疗切换的数量以及b/tsDMARDs的后期处方订单的增加,BS的使用增加了.
女性性别,疾病持续时间和当前b/tsDMARD顺序是BS偏好的关键预测因素.

结论:

大约五分之一的患者接受了BS,无论疾病类型 (axSpA与RA).
随着后期的治疗线路,BS处方率往往会增加,特别是在多次先前的b/tsDMARDs患者中.
预测BS使用的预测因素包括患者的人口统计和治疗史,突出了有针对性的BS采用机会.

关键词:

生物生物学的生物学生物类似的生物类似物处方处方处方处方处方类风湿性疾病类风湿性疾病治疗方法治疗方法

更多相关视频

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...